The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phas

Post time 2024-4-30 18:23:15

journal：Clinical Breast Cancer

Authors：Xi Chen; Xinyu Wei; Peizhuo Yao; Yanbin Liu; Haitao Guan; Huafeng Kang; Di Liu; Yan Diao; Xiaobin Ma; Weili Min; Changyou Shan; Yang Zhao; Fang Zhao; Yuanyuan Chen; Dong Xiao; Qing She; Youhuai Liu; Yinbin Zhang; Shuqun Zhang

Published date：2024-3-

DOI：10.1016/j.clbc.2024.01.018

PDF link：https://www.sciencedirect.com/sc ... 526820924000284/pdf

Article link：http://dx.doi.org/10.1016/j.clbc.2024.01.018

Article Source：Elsevier BV。

Remark：

Post time 2024-4-30 18:23:16

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phas

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phas Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phas